Calcium Gluconate Market Report 2025

The calcium gluconate market size has grown strongly in recent years. It will grow from $110.12 billion in 2024 to $118.01 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to economic growth and industrialization, increased adoption of calcium gluconate in functional foods, increasing demand for pharmaceuticals and dietary supplements, growing awareness about calcium deficiency, and regulatory support for food additives.

The calcium gluconate market size is expected to see strong growth in the next few years. It will grow to $155.89 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to an aging population and rising health consciousness, expansion of the food and beverage industry, digital marketing and e-commerce for product promotion, shift toward natural and organic products and emerging markets, and urbanization. Major trends in the forecast period include research and development in healthcare focusing on sustainable sourcing and production, the integration of calcium gluconate in medical treatments, customized formulations for specific health needs, and technological advancements in manufacturing processes.

The forecast of 7.2% growth over the next five years reflects a modest reduction of 0.8% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. emergency departments by driving up costs of calcium gluconate injections sourced from Brazil and Poland, exacerbating hypocalcemia treatment expenses and increasing critical care medication burdens. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The growth of the calcium gluconate market is expected to be driven by the increasing incidence of osteoporosis. Osteoporosis, characterized by weakened bones due to bone density and strength loss, is caused by factors such as sedentary lifestyles, insufficient calcium intake, hormonal changes, and certain medical conditions or medications. Calcium gluconate plays a crucial role in managing osteoporosis by supplementing dietary calcium intake and supporting bone health. For example, data from the Australian Institute of Health and Welfare (AIHW) in December 2023 showed that osteoporosis contributed to 2,366 deaths in 2022, with a mortality rate of 6.5 deaths per 100,000 people, accounting for 1.4% of all deaths. Additionally, there were 9,500 hospitalizations with a principal diagnosis of osteoporosis in 2021-22, translating to 89 hospitalizations per 100,000 population for individuals aged 45 and over. This increasing incidence of osteoporosis is a key driver for the growth of the calcium gluconate market.

Leading companies in the calcium gluconate market are concentrating on drug development and approval to offer effective treatments for calcium deficiencies and related health conditions. The drug development and approval process involve several stages, from initial drug discovery and preclinical testing to clinical trials and regulatory approval for market use. For instance, in September 2023, Amneal Pharmaceuticals Inc. received abbreviated new drug application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for calcium gluconate in sodium chloride injection. This product, approved with the Competitive Generic Therapy (CGT) designation and a 180-day exclusivity period, is used to treat acute symptomatic hypocalcemia in pediatric and adult patients.

The rising expenditure on healthcare is expected to drive the growth of the calcium gluconate market. Healthcare encompasses the organized system of medical services, facilities, professionals, and resources aimed at promoting, maintaining, and restoring the physical and mental health of individuals and populations. Healthcare spending is increasing due to factors such as aging populations, higher rates of chronic diseases, advancements in medical technology, and greater demand for quality healthcare services. Calcium gluconate is primarily used in healthcare to treat conditions caused by low calcium levels, including hypocalcemia, cardiac arrest, and certain types of toxicity. For example, according to economic forecasts from the Office for Budget Responsibility (OBR) and the Treasury, the UK’s planned health spending is expected to rise to £192 billion ($244.43 billion) in 2024/25, up from £182 billion ($231.7 billion) in 2022/23. Therefore, the increasing expenditure on healthcare is driving the growth of the calcium gluconate market.

Major companies operating in the calcium gluconate market are Merck & Co. Inc., Thermo Fisher Scientific Inc., Abbott Laboratories, Novartis AG, Eli Lilly and Company, Solvay, Viatris Inc., Baxter International Inc., Fresenius Kabi USA, Hikma Pharmaceuticals Inc., Amneal Pharmaceuticals Private Limited, Amphastar Pharmaceuticals, Jost Chemical Co., American Regent Inc., Coyne Chemical, Anhui Xingzhou Medicine Food Co. Ltd., Westco Chemicals Inc., Noah chemicals, ND Biotech Pvt Ltd, Global Calcium Private Limited, Foodchem, Pharma Cure Laboratories, Nivagen Pharmaceuticals Inc., Tianyi Food Additives Co. Ltd.

Europe was the largest region in the calcium gluconate market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the calcium gluconate market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the calcium gluconate market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The calcium gluconate market consists of sales of oral supplementation, calcium D-gluconate monohydrate, calcium D-gluconate gel and other injectable solutions. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment - many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The calcium gluconate market research report is one of a series of new reports that provides calcium gluconate market statistics, including the calcium gluconate industry global market size, regional shares, competitors with the calcium gluconate market share, detailed calcium gluconate market segments, market trends, and opportunities, and any further data you may need to thrive in the calcium gluconate industry. These calcium gluconate market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Calcium gluconate is a mineral supplement utilized to address calcium deficiencies and manage conditions such as hypocalcemia, osteoporosis, and specific muscle spasms. It functions by replenishing calcium levels in the body, promoting bone strength and muscle function. It can be administered intravenously or orally to restore normal calcium levels in the bloodstream.

This supplement comes in various forms such as liquid, tablet, powder, and gel. Liquid forms are substances that flow freely, taking the shape of their container and having the ability to pour and conform to container contours. They are classified into pharmaceutical grade and food grade, serving various applications in industries such as food and beverage manufacturing, pharmaceuticals, nutraceuticals, cosmetics, and personal care. Common uses include acting as emulsifiers, bulking agents, and thickening agents.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.